Skip to main content

Table 4 The most enrichment pathways related to tumorgegesis by KEGG

From: Folic Acid supplementary reduce the incidence of adenocarcinoma in a mouse model of colorectal cancer: microarray gene expression profile

Pathway ID

Pathway name

Selection Count

Count

Enrichment

mmu05219

Bladder cancer - Mus musculus (mouse)

22

44

3.709033

mmu05216

Thyroid cancer - Mus musculus (mouse)

17

31

3.597993

mmu03430

Mismatch repair - Mus musculus (mouse)

13

23

3.030142

mmu05211

Renal cell carcinoma - Mus musculus (mouse)

30

77

2.524291

mmu04520

Adherens junction - Mus musculus (mouse)

29

79

2.035831

mmu04912

GnRH signaling pathway - Mus musculus (mouse)

36

104

1.939698

mmu05214

Glioma - Mus musculus (mouse)

27

74

1.892937

mmu04110

Cell cycle - Mus musculus (mouse)

46

140

1.872654

mmu05215

Prostate cancer - Mus musculus (mouse)

31

94

1.446692

mmu04150

mTOR signaling pathway - Mus musculus (mouse)

20

56

1.429803

mmu05200

Pathways in cancer - Mus musculus (mouse)

98

345

1.369825

mmu05221

Acute myeloid leukemia - Mus musculus (mouse)

21

61

1.309804

  1. "SelectionCounts" stands for the Count of the DE genes' entities directly associated with the listed PathwayID;
  2. "Count" stands for the count of the chosen background population genes' entities associated with the listed PathwayID;